We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-24.43%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$137M
AUM Growth
+$14.4M
Cap. Flow
+$29.5M
Cap. Flow %
21.62%
Top 10 Hldgs %
90.6%
Holding
116
New
26
Increased
16
Reduced
32
Closed
31

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$13.7M
2
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$13.2M
3
EZGO
EZGO Technologies
EZGO
+$4.47M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$2.67M
5
DUO
Fangdd Network Group
DUO
+$2.19M

Top Sells

Rank Stock Value
1
BCLI
BRAINSTORM CELL THERAPUTC
BCLI
+$1.71M
2
SONN
Sonnet BioTherapeutics
SONN
+$1.61M
3
SIDU icon
Sidus Space
SIDU
+$1.16M
4
ITRM
Iterum Therapeutics
ITRM
+$1.13M
5
AKTX
Akari Therapeutics
AKTX
+$741K

Sector Composition

Rank Sector Weight
1 Healthcare 7.31%
2 Consumer Discretionary 1.12%
3 Communication Services 0.83%
4 Energy 0.67%
5 Technology 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OEF icon
1
PUT
iShares S&P 100 ETF
OEF
$19.5B
$58.5M 42.8%
3,309
-100
-3% -$20.8K
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$43.6M 31.91%
1,020
+459
+82% +$204K
IWM icon
3
iShares Russell 2000 ETF
IWM
$79.1B
$12.9M 9.44%
+73,000
New +$13.7M
SPY icon
4
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$2.56M 1.88%
+6,000
New +$2.67M
SEEL
5
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$2.17M 1.59%
+3,071
New +$13.2M
TC
6
TuanChe
TC
$58.1M
$951K 0.7%
6,099
-539
-8% -$87.6K
RCON icon
7
Recon Technology
RCON
$32.2M
$919K 0.67%
164,737
-10,501
-6% -$68.5K
BIOR
8
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$817K 0.6%
37,656
-10,605
-22% -$340K
AKTX
9
Akari Therapeutics
AKTX
$14.4M
$703K 0.51%
4,452
-4,788
-52% -$741K
TNXP icon
10
Tonix Pharmaceuticals
TNXP
$152M
$680K 0.5%
+390
New +$1.43M
RVPH
11
PUT
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$549K 0.4%
56
+9
+19% +$839
RVPH
12
CALL
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$536K 0.39%
55
-62
-53% -$5.78K
AIOS
13
AIOS Tech
AIOS
$41.8M
$528K 0.39%
11,049
-1,051
-9% -$66.6K
GCTK icon
14
GlucoTrack
GCTK
$1.87M
$526K 0.39%
334
-5
-1% -$8.98K
DOGZ icon
15
Dogness International Corp
DOGZ
$13.1M
$519K 0.38%
55,181
-3,275
-6% -$43.5K
BLRX
16
PUT
BioLineRX
BLRX
$12M
$504K 0.37%
69
+42
+156% +$2.82K
DUO
17
Fangdd Network Group
DUO
$23.5M
$479K 0.35%
+38,860
New +$2.19M
BCTXW
18
PUT
DELISTED
BriaCell Therapeutics Corp Warrant
BCTXW
$445K 0.33%
712
-136
-16% -$339
APVO icon
19
Aptevo Therapeutics
APVO
$4.96M
$440K 0.32%
+2
New +$822K
SNGX icon
20
Soligenix
SNGX
$5.36M
$413K 0.3%
46,285
-4,605
-9% -$41K
EZGO
21
EZGO Technologies
EZGO
$2.06M
$406K 0.3%
+19
New +$4.47M
BLRX
22
BioLineRX
BLRX
$12M
$382K 0.28%
+5,250
New +$353K
CKPT
23
DELISTED
Checkpoint Therapeutics
CKPT
$349K 0.26%
+205,247
New +$466K
RDHL
24
Redhill Biopharma
RDHL
$4.15M
$324K 0.24%
+25,400
New +$664K
PULM icon
25
Pulmatrix
PULM
$6.1M
$307K 0.22%
151,350
-32,724
-18% -$80.7K
1
2 3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2023 Portfolio in Review

As of Q3 2023, Sabby Management held 116 positions worth $137M, up 12% from $122M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Sabby Management deployed $29.5M of net new capital in Q3 2023, opening 26 new positions and adding to 16 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 73,000 shares worth $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 7.3% of assets, down from 15% a quarter earlier, followed by Consumer Discretionary and Communication Services.

On the sell side, the largest reduction was BRAINSTORM CELL THERAPUTC, an estimated $1.71M trimmed.

  • Sabby Management's largest Q3 2023 buy was iShares Russell 2000 ETF: 73,000 shares worth $12.9M.
  • Sabby Management added most to Neptune Wellness Solutions Inc. Ordinary Shares in Q3 2023, an estimated $799K increase.
  • Sabby Management's biggest Q3 2023 reduction was BRAINSTORM CELL THERAPUTC, cutting an estimated $1.71M.
  • Sabby Management fully exited Sonnet BioTherapeutics in Q3 2023, selling an estimated $1.61M.
  • Sabby Management's ten largest holdings make up 91% of its $137M portfolio in Q3 2023.
  • Sabby Management opened 26 new positions and closed 31 in Q3 2023.
  • Sabby Management's portfolio value rose 12% quarter-over-quarter to $137M.

Based on Sabby Management's 13F filing for Q3 2023, filed 14 Nov 2023.